CD274 and non-small cell lung carcinoma: Specifically speaking, younger patients received a better OS benefit in advanced or metastatic lung cancer patients with anti-PD-1/PD-L1 inhibitors, Pembrolizumab or Atezolizuma used, NSCLC, squamous and subsequent-line setting, while older patients had an advantage over other conventional therapies in patients with advanced or metastatic lung cancer, especially for those patients with anti-PD-1/PD-L1 inhibitors, NSCLC, non-squamous, Pembrolizumab, Atezolizumab or Ipilimumab used and subsequent-line setting.